Aspirin suppository

1. Analgesic effect: It is mainly through inhibiting the synthesis of prostaglandins and other substances that can make pain sensitive to mechanical or chemical stimulation (such as bradykinin, histamine), and it is a peripheral analgesic. However, the possibility of central analgesia (possibly acting on the hypothalamus) cannot be ruled out; 2. Anti-inflammatory effect: The exact mechanism is still unclear. It may be due to the fact that this product acts on inflamed tissues and inhibits the synthesis of prostaglandins or other substances that can cause inflammatory reactions (such as histamine) to play an anti-inflammatory role. Inhibition of the release of lysosomal enzymes and leukocyte chemotaxis may also be related to it; 3. Antipyretic effect: It may act on the hypothalamic temperature regulation center to cause peripheral vasodilation, increased skin blood flow, sweating, and increased heat dissipation to play an antipyretic role. This central effect may be related to the inhibition of prostaglandin synthesis in the hypothalamus; 4. Anti-rheumatic effect: The anti-rheumatic mechanism of this product, in addition to antipyretic and analgesic effects, is mainly anti-inflammatory; 5. Inhibition of platelet aggregation: It works by inhibiting platelet cyclooxygenase and reducing the production of prostaglandins.

aspirin

This product is a milky white or slightly yellow suppository.

It is used to treat fever caused by the common cold or influenza. It is also used to relieve mild to moderate pain, such as headache, toothache, neuralgia, muscle pain, dysmenorrhea and joint pain.

Rectal administration. Adults take 1 tablet (0.3g) at a time. If fever or pain persists, repeat the medication every 4 to 6 hours. Do not exceed 4 tablets in 24 hours. Children aged 1 to 6 years old take 1 tablet (0.1g) at a time. If fever or pain persists, repeat the medication every 4 to 6 hours. Do not exceed 4 tablets in 24 hours.

The doses generally used for antipyretic and analgesic rarely cause adverse reactions. Long-term and large-scale use of the drug (such as the treatment of rheumatic fever), especially when the blood concentration of the drug is >200mu;g/ml, is more likely to cause adverse reactions. The higher the blood concentration, the more obvious the adverse reactions. 1. Common gastrointestinal reactions include nausea, vomiting, upper abdominal discomfort or pain (caused by the direct stimulation of the gastric mucosa by this product) (incidence rate 3%~9%), which usually disappear after stopping the drug. Long-term or large-dose use may cause gastrointestinal bleeding or ulcers. 2. Central nervous system: reversible tinnitus and hearing loss occur, which usually occur after a certain course of treatment and the blood concentration reaches 200~300mu;g/L. 3. Allergic reaction: occurs in 0.2% of patients, manifested as asthma, urticaria, angioedema or shock. Most

1. Active ulcer disease or other causes of gastrointestinal bleeding. 2. Hemophilia or thrombocytopenia. 3. People with a history of allergy to aspirin or other nonsteroidal anti-inflammatory drugs, especially those with asthma, angioedema or shock.

1. The efficacy is not enhanced when used with other non-steroidal anti-inflammatory analgesics, because this product can reduce the bioavailability of other non-steroidal anti-inflammatory drugs. In addition, gastrointestinal side effects (including ulcers and bleeding) are increased; in addition, due to the enhanced inhibitory effect on platelet aggregation, the risk of bleeding in other parts may also be increased. Long-term and large-scale use of this product with acetaminophen may cause kidney diseases including renal papillary necrosis, renal cancer or bladder cancer. 2. When used with any drug that can cause hypoprothrombinemia, thrombocytopenia, reduced platelet aggregation function or gastrointestinal ulcer bleeding, there may be a risk of aggravating coagulation disorders and causing bleeding. 3. When used with anticoagulants (dicoumarins, heparin, etc.) and thrombolytics (streptokinase, urokinase), the risk of bleeding may be increased. 4. Urine alkalinizing drugs (sodium bicarbonate, etc.) and antacids (long-term and large-scale use) can increase the excretion of this product in urine and reduce the blood drug concentration. However, when the blood concentration of this product has reached a stable state and the alkaline drug is discontinued, the blood concentration of this product can be increased to a toxic level. Carbonic anhydrase inhibitors can alkalinize urine, but can cause metabolic acidosis, which can not only reduce the blood concentration, but also increase the amount of this product penetrating into the brain tissue, thereby increasing toxic reactions. 5 Uric acid drugs can reduce the excretion of this product and increase its blood concentration. Patients whose blood concentration of this product has reached a stable state may increase the blood concentration of this product and increase toxic reactions after adding uricidifying drugs. 6 Glucocorticoids (hormones for short) can increase the excretion of salicylates. When used together, the dose of this product should be increased if necessary to maintain the blood concentration of this product. Long-term use of this product and hormones, especially when used in large quantities, increases the risk of gastrointestinal ulcers and bleeding. For this reason, it is not recommended to use these two drugs at the same time in clinical practice. 7 The hypoglycemic effect of insulin or oral hypoglycemic drugs can be enhanced and accelerated by using them together with this product. 8 When used with methotrexate (MTX), it can reduce the binding of methotrexate to proteins, reduce its excretion from the kidneys, increase blood drug concentrations and increase toxic reactions. 9 The uric acid excretion effect of probenecid or sulfinpyrazone can be reduced by the simultaneous use of this product; when the blood concentration of salicylate is >50mu;g/ml, it will be significantly reduced, and it will be even more so when it is >100-150mu;g/ml. In addition, probenecid can reduce the clearance rate of salicylate from the kidneys, thereby increasing the latter's blood concentration.

Sealed and stored in a cool and dry place.

0.1 g

Sunflower Pharmaceutical Group (Jizhou) Co., Ltd.

• Founded in:

  2001-04-27

• Address:

  No. 588, Yongxing West Road, Jizhou District, Hengshui City

• Tax NO.:

  91131181601682772X

• Registered Funds:

  76.08 million yuan

• Website:

  Log in to view

• Email:

  Log in to view